| Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. | |
| | |
MedLine Citation:
|
PMID: 17603511 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Graft failure is a life-threatening complication of allogeneic stem cell transplantation (SCT). We assessed the feasibility of performing a second SCT after such failure when fludarabine and antithymocyte globulin (ATG) are used for non-myeloablative conditioning and tacrolimus for graft-versus-host disease (GVHD) prophylaxis. Nine patients with SCTs for various hematologic malignancies were enrolled, eight with primary and one with secondary graft failure. The median time between the first and second SCT was 53 days. Eight patients had the same donor for their second SCT, and one had a cord blood transplant. Three patients were not evaluable because of early death; the other six had evidence of donor cell engraftment. Six of the nine patients developed acute grade II-IV GVHD, the main cause of death. Overall, we found that fludarabine and ATG conditioning before a second SCT allows engraftment of donor hematopoiesis. Future studies should include more intense GVHD prophylaxis. |
| | |
Authors:
|
E Jabbour; G Rondon; P Anderlini; S A Giralt; D R Couriel; R E Champlin; I F Khouri |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2007-07-02 |
Journal Detail:
|
Title: Bone marrow transplantation Volume: 40 ISSN: 0268-3369 ISO Abbreviation: Bone Marrow Transplant. Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-08-16 Completed Date: 2007-11-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8702459 Medline TA: Bone Marrow Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 431-5 Citation Subset: IM |
Affiliation:
|
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antilymphocyte Serum / administration & dosage* Feasibility Studies Female Graft Rejection Graft Survival Graft vs Host Disease / drug therapy, prevention & control Hematopoiesis Hematopoietic Stem Cell Transplantation / adverse effects, methods* Humans Male Middle Aged Pilot Projects Salvage Therapy / methods* Tacrolimus / therapeutic use Transplantation Conditioning / methods* Transplantation, Autologous Vidarabine / administration & dosage, analogs & derivatives* |
| Chemical | |
Reg. No./Substance:
|
0/Antilymphocyte Serum; 109581-93-3/Tacrolimus; 21679-14-1/fludarabine; 5536-17-4/Vidarabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Irreversible cell-cycle transitions are due to systems-level feedback.
Next Document: Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine...